| 31.18 Data as of May 24 |  -0.57 / -1.81%Today’s Change | 20.50 Today|||52-Week Range 32.09 | +13.57% Year-to-Date |
| Favorable Verdict for Mylan - Analyst Blog May 22 / Zacks.com | Actavis: The latest Fortune 500 company to "leave" the U.S. for tax reasons May 21 / Fortune |
| Merck Enters into Strategic Deal - Analyst Blog May 22 / Zacks.com | Actavis: What it's like to join the Fortune 500 May 10 / Fortune |
| Generic Launches at Mylan Continue - Analyst Blog May 22 / Zacks.com | Women CEOs in the Fortune 500 May 09 / Fortune |
| Previous close | 31.75 |
| Today’s open | 31.69 |
| Day’s range | 31.04 - 31.69 |
| Volume | 5,952,812 |
| Average volume (3 months) | 6,209,817 |
| Market cap | $11.9B |
| Dividend yield | -- |
| Earnings growth (last year) | +24.59% |
| Earnings growth (this year) | +10.78% |
| Earnings growth (next 5 years) | +10.00% |
| Revenue growth (last year) | +11.49% |
| P/E ratio | 20.8 |
| Price/Sales | 1.67 |
| Price/Book | 3.69 |
| Today’s change | Today’s % change | |
|---|---|---|
| PRGOPerrigo Co | +1.06 | +0.90% |
| FRXForest Laboratories ... | -0.30 | -0.76% |
| BMRNBioMarin Pharmaceuti... | -1.37 | -2.08% |
| ZTSZoetis Inc | +0.62 | +1.89% |
| Next reporting date | July 31, 2013 |
| EPS forecast (this quarter) | $0.67 |
| Annual revenue (last year) | $6.8B |
| Annual profit (last year) | $640.9M |
| Net profit margin | 9.37% |
Sector Health Technology |
Industry Pharmaceuticals: Generic |
Chief Executive Officer & Director Heather M. Bresch, MBA |
President & Director Rajiv Malik, MBA |
Corporate headquarters Canonsburg, Pennsylvania |
.
